Anika Therapeutics (ANIK) Return on Capital Employed (2011 - 2026)

Anika Therapeutics (ANIK) has 16 years of Return on Capital Employed data on file, last reported at 7.48% in Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 363.0% year-over-year to 7.48% in Q1 2026; TTM through Mar 2026 was 7.48%, a 363.0% decrease from a year earlier, with the FY2025 full-year figure at 6.33%, down 394.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 7.48%, down from 6.58% in the prior quarter.
• Over the last five years, Return on Capital Employed for ANIK reached as high as 9.17% in Q3 2024 and fell as low as 7.48% in Q1 2026.
• Historically, Return on Capital Employed has averaged 1.8% across 5 years, with a median of 2.48% in 2023.
• Across the five-year window, Return on Capital Employed surged 1165 bps in 2024 and slumped 1648 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 1.15% in 2022, then sank by 73 bps to 0.31% in 2023, then plunged by 937 bps to 2.63% in 2024, then plunged by 150 bps to 6.58% in 2025, then decreased by 14 bps to 7.48% in 2026.
• Per Business Quant data, the three most recent Return on Capital Employed figures were 7.48% in Q1 2026, 6.58% in Q4 2025, and 7.32% in Q3 2025.